Seekyo Therapeutics

📍 Futuroscope, France🗓 Founded 2018👥 9 employees💰 Last funded 2024
Biotechnology Research🌐 seekyo-therapeutics.com
Website LinkedIn
The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal…) • Low Cost of Goods
3
Total investors
2
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
2
United States
1
Investor activity2019–2024 · investors recorded per year
2019220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Seekyo Therapeutics?
Seekyo Therapeutics has 3 investors on record on gritt.io, including 2 early-stage backers and 1 late-stage investors.
When did Seekyo Therapeutics last raise funding?
The most recent investment in Seekyo Therapeutics recorded on gritt.io was in 2024.
When was Seekyo Therapeutics founded?
Seekyo Therapeutics was founded in 2018.
What industry is Seekyo Therapeutics in?
Seekyo Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Seekyo Therapeutics based?
Seekyo Therapeutics is headquartered in Futuroscope, France.